A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03520478 |
Recruitment Status :
Active, not recruiting
First Posted : May 9, 2018
Last Update Posted : March 2, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostate Cancer Hormone-Dependent Prostate Cancer | Drug: SHR3680 Drug: Bicalutamide | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 654 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase III, Multicenter, Randomized, Open Study of SHR3680 Compared to Bicalutamide in the Treatment of Patients With Hormone Sensitive Prostate Cancer |
Actual Study Start Date : | May 30, 2018 |
Estimated Primary Completion Date : | April 30, 2023 |
Estimated Study Completion Date : | April 30, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: SHR3680
Participants will receive SHR3680 orally
|
Drug: SHR3680
Tablet. Specifications of 80 mg; orally, once a day |
Active Comparator: bicalutamide
Participants will receive bicalutamide orally
|
Drug: Bicalutamide
Tablet. Specifications of 50 mg; orally, once a day |
- rPFS [ Time Frame: Approximately 70 months ]Time from randomisation to radiologically confirmed progressive disease or death due to any cause
- OS [ Time Frame: Approximately 70 months ]Time from randomisation to death due to any cause
- Time to prostate specific antigen (PSA) progression [ Time Frame: Approximately 70 months ]Time from randomisation to the first time of PSA progression according to the criterion of PCGW3
- Time to skeletal-related events [ Time Frame: Approximately 70 months ]Time from randomisation to the first occurrence of a fracture or treatment for the fracture. The skeletal-related event is defined as the occurrence of either pathological or clinical fracture, spinal cord compression, bone-related radiotherapy or surgery
- Objective response rate (ORR) [ Time Frame: Approximately 70 months ]The percentage of subjects with measureable disease at baseline who achieved a complete or partial response in their soft tissue disease using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria
- Time to initiation of a new antineoplastic therapy [ Time Frame: Approximately 70 months ]Time from randomisation to the initiation of antineoplastic subsequent to the study treatment
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age≧18 year, male;
- ECOG performance scale 0 to 1;
- Histologically or cytological confirmed prostate adenocarcinoma without neuroendocrine differentiation or small cell features ;
- Adequate hepatic, renal, heart, and hematological functions;
- Patients have given voluntary written informed consent before performance of any study-related procedure not part of normal medical care,with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
Exclusion Criteria:
- Subject has received any prior radiation therapy or surgery for prostate cancer, except 1 course of palliative surgical therapy if it was used at least 4 weeks prior to day 1;
- Previous use or are using a second-generation androgen receptor antagonist (enzalutamide, ARN-509, ODM-201), abiraterone, ketoconazole for prostate cancer, or other agents that will inhibit the production of androgens;
- Have participated in an interventional clinical trial or been treated with the following drugs in the past 4 weeks prior to day 1: 5-alpha reductase inhibitors, estrogen, progestin, and herbal products known to decrease PSA levels ;
- Evidence of brain metastasis or primary tumors;
- Planned to initiate any other anti-tumor therapies during the study;
- Unable to swallow, chronic diarrhea and intestinal obstruction, or the presence of a variety of other factors that affect drug use and absorption; Clinically significant cardiovascular diseases;
- History of seizure or certain conditions that may predispose to seizure;
- Severe concurrent disease and infection that, in the judgment of the investigator, would make the patient inappropriate for enrollment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03520478
Principal Investigator: | Dingwei Ye, M.D. | Fudan University |
Responsible Party: | Jiangsu HengRui Medicine Co., Ltd. |
ClinicalTrials.gov Identifier: | NCT03520478 |
Other Study ID Numbers: |
SHR-3680-III-HSPC |
First Posted: | May 9, 2018 Key Record Dates |
Last Update Posted: | March 2, 2021 |
Last Verified: | February 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Hormone sensitive prostate cancer SHR3680 Anti-androgen receptor |
Prostatic Neoplasms Hypersensitivity Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Male Genital Diseases Urogenital Diseases |
Prostatic Diseases Male Urogenital Diseases Immune System Diseases Bicalutamide Androgen Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents |